^
Association details:
| Biomarker: | BTK C481S + PLCG2 D1140N |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
BTK AND PLCG2 MUTATIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RELAPSING ON IBRUTINIB: A EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC) STUDY BASED ON REAL-WORLD EVIDENCE
Published date:
06/12/2020
Excerpt:
Thirty-one of 59 (53%) R/R pts carried at least 1 hotspot BTK mutation (p.C481S/R/Y) (median VAF 23.3%, range, 1.4%>97.3%) (Table 1). Eight of 31 (26%) mutated pts carried ≥2 hotspot BTK mutations with different VAFs. Seven R/R pts harboring BTK mutation(s) also carried PLCG2 mutation(s) (Table 1). This study reveals that ~50% of pts relapsing on ibrutinib had a BTK p.C481 mutation by NGS.
